Quality of Life Still Good with HIPEC Surgery for Peritoneal Mesothelioma
This study shows that the improvement in quality of life can be very significant compared with the preoperative status,” Levine said. “By six months, virtually all of the patients had recovered to preoperative baseline or better quality-of-life measures.” The post Quality of Life Still Good with HIPEC Surgery for Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - May 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Clinical Trial Exploring Family Predisposition
The National Cancer Institute has opened a clinical trial using mesothelioma patients and their family members to explore predisposition to the cancer and potential solutions to negating it. The trial is a follow up to an earlier study of a genetic mutation that creates susceptibility to various cancers but a longer-than-normal survival with platinum-based chemotherapy treatment. “This is an important, long-term study that could have implications not only for a patient, but for family members, too,” Dr. Raffit Hassan, NCI senior investigator told The Mesothelioma Center at Asbestos.com. “Progress can be m...
Source: Asbestos and Mesothelioma News - May 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Latest T-Cell Study Opens for Mesothelioma Patients
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - May 16, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Radiotherapy Can Double Two-Year Survival for Mesothelioma
A novel radiotherapy regimen can double the chances of surviving two or more years with pleural mesothelioma, according to Dr. Marco Trovo at University Hospital of Udine in Italy. Trovo is the lead author of a study involving 108 patients treated for malignant mesothelioma between 2014 and 2018 at the National Cancer Institute in Aviano, Italy. He presented the findings this week at the annual European Society for Therapeutic Radiology and Oncology convention in Milan. “Radiotherapy has evolved dramatically in the last few years, so we wanted to see if it could now be used to prevent cancer from spreading to nearby ...
Source: Asbestos and Mesothelioma News - May 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Elderly Mesothelioma Patients Denied Valuable Survival Time
Almost two-thirds of the elderly patients being diagnosed with mesothelioma are dying without receiving any cancer-related treatment that could significantly extend survival. Median survival is just 4.1 months, according to the first extensive study of mesothelioma patients 80 years or older. The Annals of Surgical Oncology published the recent study, authored by mesothelioma specialists at five highly rated medical facilities. “Too many elderly patients are being denied valuable survival time,” Dr. Charles B. Simone II, chief medical officer at the New York Proton Center and co-author of the study, told The M...
Source: Asbestos and Mesothelioma News - May 13, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA Ignored Advice from Staff Experts When Issuing New Asbestos Rule
More than a dozen senior officials and experts at the Environmental Protection Agency urged the EPA to ban asbestos outright, a new report shows. Two internal memos obtained by the Asbestos Disease Awareness Organization and shared with the New York Times reveal the EPA’s own scientists and lawyers advised the agency to issue a complete ban of asbestos instead of the recent regulations that only restricted its domestic use. In the memos, dated Aug. 10, 2018, EPA staff members wrote that the agency “should seek to ban all new uses of asbestos because the extreme harm from this chemical substance outweighs any ...
Source: Asbestos and Mesothelioma News - May 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

High-Dose Radiotherapy Boosts Survival Rate in Mesothelioma High-Dose Radiotherapy Boosts Survival Rate in Mesothelioma
Patients who underwent nonradical surgery and received high doses of radiotherapy were twice as likely to be alive at 2 years compared to those who received palliative radiotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel Imaging May Make Peritoneal Mesothelioma Surgery More Effective
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - May 6, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

NIOSH Asking for National Mesothelioma Registry Input
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry. NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted. Comments must be received by July 8, 2019. “NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, an...
Source: Asbestos and Mesothelioma News - May 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Radical Hemithoracic Radiation Tx Ups Survival in Mesothelioma
WEDNESDAY, May 1, 2019 -- For patients with malignant pleural mesothelioma (MPM), overall survival (OS) is significantly improved with radical hemithoracic radiotherapy (RHR) versus palliative radiotherapy (PR), according to a study presented at... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2019 Category: Pharmaceuticals Source Type: news

Radiotherapy doubles survival for patients with mesothelioma
(European Society for Radiotherapy and Oncology (ESTRO)) Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented at the ESTRO 38 conference. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2019 Category: International Medicine & Public Health Source Type: news

Optimism High for Mesothelioma Immunotherapy Clinical Trial in Europe
A novel clinical trial aiming to train the immune system to recognize and attack pleural mesothelioma tumor cells has opened with considerable optimism across five European countries. The randomized phase II/III study is designed to measure the efficacy and anti-tumor activity of MesoPher, a vaccine combining a patient’s own dendritic immune cells with a specially engineered cell line. The multicenter study, which is hoping for 235 participants, has opened in Antwerp, Belgium; Lille, France; Ancona, Italy; Amsterdam and Rotterdam, Netherlands and Leicester, England. “There is hope, a lot of hope, with this stud...
Source: Asbestos and Mesothelioma News - April 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA ’s Latest Asbestos Regulation Falls Short of Full Ban
The Environmental Protection Agency issued a new regulation on Wednesday that will make it tougher to domestically manufacture, import or sell products made with asbestos, the toxic mineral that causes mesothelioma and other diseases. The regulation closes a loophole in the partial ban of asbestos that was legislated almost 30 years ago. It will strengthen the EPA’s ability to review and prohibit the use of a long list of asbestos products that are not banned but have been long abandoned by the industry. The ruling is part of a legislative process that requires the EPA to review its regulation of asbestos under the...
Source: Asbestos and Mesothelioma News - April 18, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1
Malignancies arising from mutation of tumor suppressors have unexplained tissue proclivity. For example, BAP1 encodes a widely expressed deubiquitinase for histone H2A, but germline mutations are predominantly associated with uveal melanomas and mesotheliomas. We show that BAP1 inactivation causes apoptosis in mouse embryonic stem cells, fibroblasts, liver, and pancreatic tissue but not in melanocytes and mesothelial cells. Ubiquitin ligase RNF2, which silences genes by monoubiquitinating H2A, promoted apoptosis in BAP1-deficient cells by suppressing expression of the prosurvival genes Bcl2 and Mcl1. In contrast, BAP1 loss...
Source: ScienceNOW - April 18, 2019 Category: Science Authors: He, M., Chaurushiya, M. S., Webster, J. D., Kummerfeld, S., Reja, R., Chaudhuri, S., Chen, Y.-J., Modrusan, Z., Haley, B., Dugger, D. L., Eastham-Anderson, J., Lau, S., Dey, A., Caothien, R., Roose-Girma, M., Newton, K., Dixit, V. M. Tags: Genetics, Medicine, Diseases reports Source Type: news

EPA Removes Part of Libby Asbestos Cleanup from Superfund List
The U.S. Environmental Protection Agency has deleted a 45-acre portion of the Libby Asbestos Superfund site from the National Priorities List. The EPA and the Montana Department of Environmental Quality have agreed that institutional controls to prevent any future exposure to asbestos in the area were satisfied. It’s a step closer to finishing the decontamination of the longest-running, man-made environmental disaster in American history. The sprawling Superfund site, which was placed on the National Priorities List in 2002, was originally divided into eight operable units. The units were based upon the extent of co...
Source: Asbestos and Mesothelioma News - April 16, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cancer-Related Insomnia: New Research Finds Effective Treatments
This study was a first of its kind. It involved a head-to-head comparison of acupuncture and cognitive behavioral therapy, enrolled patients with many different types of cancer and included nearly 30% minority participants. Previous studies focused solely on breast cancer and included 90% white participants. Limitations of the previous research make it difficult to determine if the results are applicable to patients with other cancers and people of diverse backgrounds. Cognitive Behavioral Therapy and Acupuncture Are Effective Acupuncture and cognitive behavioral therapy treatments produced clinically meaningful reduction...
Source: Asbestos and Mesothelioma News - April 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Therapy Trial for Mesothelioma Opens Internationally
A long-awaited phase III clinical trial of a novel gene therapy could change malignant pleural mesothelioma treatment in the future. The trial, which will include almost 50 locations around the world, opens this month for mesothelioma patients whose standard treatment has stopped working. The gene therapy drug, called TR002, is also a form of immunotherapy. It will be used in combination with gemcitabine chemotherapy in a second-line setting. “We can’t predict what the outcome will be, but we’re very excited about the potential of this treatment, and the fact there may be another drug in the armamentarium...
Source: Asbestos and Mesothelioma News - April 8, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Mesothelioma Tissue Bank Identifies Survival Factors
This study was on the exploration of risk factors affecting mortality.” The Lancet Respiratory Medicine published the findings early in 2019. Factors Associated with Longer Survival Age under 45 years when diagnosed Female gender Peritoneal mesothelioma subtype Epithelioid histology subtype Treatment including surgery and chemotherapy Stage 1 at time of diagnosis “The identification of these factors could help patients at risk for therapy failure who may benefit from novel interventions, or avoiding treatments that are not effective, or with high mortality risk,” the re...
Source: Asbestos and Mesothelioma News - April 2, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Survival Improves for Peritoneal Mesothelioma Patients in Finland
Survival time improved significantly for peritoneal mesothelioma patients in Finland who underwent a combination of surgery and chemotherapy, according to a recently released study. The five-year survival rate was 66 percent. The median survival was 62 months. According to a smaller, previous study in Finland, the median survival without treatment was just four months after diagnosis. “Despite these advances in treatment…the majority of patients with malignant peritoneal mesothelioma receive only palliative care of systemic chemotherapy, leaving many eligible patients without the benefit of this more invasive...
Source: Asbestos and Mesothelioma News - April 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New immnotherapy can shrink otherwise untreatable breast, lung and mesothelioma tumors
Researchers at Memorial Sloan Kettering have deveoped the world's first immunotherapy that can shrink treatment-resistant lung, breast and mesothelioma tumors in some two million patients. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2019 Category: Consumer Health News Source Type: news

Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors
(American Association for Cancer Research) A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news

New Jersey Jury Finds J & J Not Liable in Latest Talc Cancer Trial New Jersey Jury Finds J & J Not Liable in Latest Talc Cancer Trial
A New Jersey jury on Wednesday cleared Johnson& Johnson of liability in a lawsuit brought by a man who said that asbestos in the company's talcum powder products caused his mesothelioma.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Better Muscle Mass Linked to Improved Immunotherapy Response
Researchers at Osaka University in Japan have identified a key component of physical health associated with response to immunotherapy drugs. Among people with non-small cell lung cancer, higher levels of muscle mass predicted a better response to PD-1 inhibitor immunotherapy. Sarcopenia — the term used to describe low muscle mass levels — appears to reduce the benefits a person receives from immunotherapy cancer treatment. “Sarcopenia at baseline is a significant predictor of worse outcome in patients with advanced NSCLC [non-small cell lung cancer] receiving PD-1 blockade,” the study investigators ...
Source: Asbestos and Mesothelioma News - March 28, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Jersey jury finds J & J not liable in talc cancer trial; company settles three other cases
A New Jersey jury on Wednesday cleared Johnson& Johnson of liability in a lawsuit brought by a man who said that asbestos in the company's talcum powder products caused his mesothelioma. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Specialist cancer nurse for armed forces to full-time post
The first mesothelioma clinical nurse specialist in the UK to focus on patients with an armed forces or military background has had her funding extended so she can become whole-time equivalent. (Source: Nursing Times)
Source: Nursing Times - March 28, 2019 Category: Nursing Source Type: news

Specialist cancer nurse for armed forces to be full-time post
The first mesothelioma clinical nurse specialist in the UK to focus on patients with an armed forces or military background has had her funding extended so she can become whole-time equivalent. (Source: Nursing Times)
Source: Nursing Times - March 28, 2019 Category: Nursing Source Type: news

J & J settles three mesothelioma talc cases-plaintiffs' lawyer
Johnson& Johnson has settled three cases brought by plaintiffs who claimed asbestos in the company's talcum-based products caused mesothelioma, an attorney for the plaintiffs' said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

US Geological Survey: 750 Metric Tons of Asbestos Imported in 2018
The United States imported an estimated 750 metric tons of raw asbestos in 2018, more than double the total in 2017 and the most entering the country since 2013, according to the recently released U.S. Geological Survey Mineral Commodity Summaries report. For the first time, all of the imported asbestos went to the chloralkali industry, which uses it to manufacture semipermeable diaphragms to make chlorine. The report was prepared by Daniel Flanagan, a mineral commodity specialist for the National Minerals Information Center at the U.S. Geological Survey. It is part of the U.S. Department of the Interior. Asbestos consume...
Source: Asbestos and Mesothelioma News - March 26, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pacific Mesothelioma Center Moves Closer to Treatment Breakthrough
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - March 25, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Supreme Court Rules to Protect Navy Veterans in Asbestos Case
The U.S. Supreme Court ruled Tuesday that manufacturers are liable for asbestos-containing materials they did not make, distribute or install, but were needed for their equipment to function properly. The maritime-law ruling involved Navy veterans who were not warned about the danger of asbestos insulation added by a third party to pumps, turbines and blowers aboard three different ships. The ruling will allow cases filed originally by Navy veterans Kenneth McAfee and John DeVries to move forward against five manufacturers. Both veterans died from cancer during the course of litigation. The deaths have been attributed to a...
Source: Asbestos and Mesothelioma News - March 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

US Launches First National Firefighter Cancer Registry
The National Institute for Occupational Safety and Health has launched the first nationwide Firefighter Cancer Registry, linking workplace exposures to deadly malignancies such as mesothelioma. Officials administering the study believe the registry will help reduce the incidence of various cancers for firefighters. “A national registry will go a long way toward answering the many questions still out there,” Dr. Kenny Fent, an industrial hygienist at NIOSH who is leading the effort, told The Mesothelioma Center at Asbestos.com. “We’re just laying the groundwork now, but in the long run, we want to h...
Source: Asbestos and Mesothelioma News - March 18, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Woman awarded $29 million in Johnson Johnson baby powder cancer case
(Natural News) Johnson & Johnson has been ordered to pay $29 million after a California jury determined that its baby powder contributed substantially to a woman’s mesothelioma. The immensely popular product, which has been widely used on babies and adults alike for decades, is the target of more than 13,000 similar lawsuits that have been... (Source: NaturalNews.com)
Source: NaturalNews.com - March 17, 2019 Category: Consumer Health News Source Type: news

Health Highlights: March 15, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Jury Awards $29.4 Million in Talcum Powder/Cancer Case A woman who said her mesothelioma was caused by her regular use of Johnson&... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 15, 2019 Category: General Medicine Source Type: news

Johnson & Johnson hit with $29.4 million verdict in talcum powder case
A California jury returned a $29.4 million verdict in a trial involving a woman who believes that her mesothelioma is tied to her regular use of Johnson& Johnson's talcum powder. (Source: CNN.com - Health)
Source: CNN.com - Health - March 14, 2019 Category: Consumer Health News Source Type: news

California Jury Awards $29 Million to Woman Who Says She Got Cancer from Johnson & Johnson Baby Powder
A woman who claims asbestos in Johnson & Johnson products caused her deadly cancer was awarded $29.4 million by a California jury on Wednesday, Reuters reports. A jury in a California Superior Court in Oakland determined that defective Baby Powder was a “substantial contributing factor” to Terry Leavitt’s mesothelioma, an aggressive cancer that affects the tissue that coats internal organs, the Associated Press reports. Leavitt said she often used two talcum-powder-based Johnson & Johnson products — Baby Powder and Shower to Shower powder — in the 1960s and 1970s, and claims they contr...
Source: TIME: Health - March 14, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer onetime Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA: Asbestos Confirmed in Children ’ s Makeup
The U.S. Food and Drug Administration on Tuesday confirmed the 2017 finding of asbestos contamination in children’s cosmetic products sold by retailers Claire’s and Justice. FDA Commissioner Scott Gottlieb and Susan Mayne, director of the Center for Food Safety and Applied Nutrition, released a joint statement announcing the results of independent tests that confirmed asbestos contamination in three of the product samples from Claire’s and one of the samples from Justice. Asbestos is a naturally occurring mineral often found near talc, a key ingredient in many cosmetic products. Exposure to asbestos can...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Targeting Blood-Clotting Pathway Improves Mesothelioma Treatment
A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published ...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Belgian EPP Study Shows Mesothelioma Surgery Extends Survival
Using proper patient selection, doctors in Leuven, Belgium, are extending mesothelioma survival times significantly with the controversial extrapleural pneumonectomy surgery. Despite a growing reluctance to perform the surgery within the United States and throughout much of Europe, mesothelioma specialists at University Hospitals KU Leuven have continued performing it with great success. Their 2018 single-center study of the extrapleural pneumonectomy (EPP) for pleural mesothelioma produced a 33.2-month median survival and a 24.2 percent five-year survival. “With our dedicated team, a patient can do well with this su...
Source: Asbestos and Mesothelioma News - March 4, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Targeting Certain Lymph Nodes Could Change Mesothelioma Treatment
Thoracic surgeon Dr. Joseph Friedberg at the University of Maryland School of Medicine has identified previously underutilized lymph nodes that could change the way pleural mesothelioma is diagnosed, staged and treated. Friedberg is the head of the Division of Thoracic surgery at Maryland and director of the Mesothelioma and Thoracic Oncology Treatment and Research Center. The findings are based upon the posterior intercostal lymph nodes — a part of the lymphatic system between the ribs near the spine — in 56 mesothelioma patients who were part of a recent clinical trial. Friedberg detailed the groundbreaking f...
Source: Asbestos and Mesothelioma News - February 26, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Faces Federal Subpoenas on Asbestos in Its Baby Powder
Johnson & Johnson executives this week revealed the Department of Justice and the Securities and Exchange Commission issued subpoenas related to ongoing lawsuits over the company’s alleged asbestos contamination in its popular talcum powder. The company disclosed the federal inquiries in its annual report to the SEC on Wednesday. It was the first time the pharmaceutical giant admitted that federal agencies had subpoenaed the company about its talc products. Despite thousands of lawsuits and a 2017 report that showed J&J executives were aware of the asbestos liabilities since the 1970s, company officials deny ...
Source: Asbestos and Mesothelioma News - February 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - February 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Talc Supplier Imerys Files for Bankruptcy Over Cancer Lawsuits
Seeking protection from rapidly mounting litigation, Imerys Talc America and two of its subsidiaries filed for Chapter 11 bankruptcy protection Wednesday in Delaware. Imerys is a major talc supplier for Johnson & Johnson consumer goods, including the company’s iconic baby powder and Shower to Shower line. Litigants claim the talc-based products were contaminated with asbestos, leading to cases of mesothelioma and ovarian cancer. The bankruptcy filing comes in the midst of an ongoing, high-profile trial in California in which a woman is blaming Imerys talc for her mesothelioma, a rare cancer caused almost exclus...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemo-Carrying Gold Nanoparticles Tested on Mesothelioma
Italian researchers have found early success using gold nanoparticles as a chemotherapy-delivery vehicle for mesothelioma. They are hopeful their discovery will lead to an improvement in mesothelioma treatment in the future. The researchers tested their strategy on pleural mesothelioma cells in the lab. They first designed gold nanoparticles with a specific antibody targeted to the cells. Then they loaded the chemotherapy drug Alimta (pemetrexed) into the nanoparticles and observed its effect on the cancer cells. Delivering Alimta through the gold nanoparticles proved more effective than standard chemotherapy. But the me...
Source: Asbestos and Mesothelioma News - February 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Immunotherapy Combination Gaining Momentum
Recent studies from France and the Netherlands have shown patients with pleural mesothelioma can benefit significantly from a second-line immunotherapy drug combination. In separate phase II studies, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) created a synergy that helped stop or slow tumor growth after traditional chemotherapy had failed. “Our results add to the growing evidence that immunotherapy is a promising treatment,” wrote lead author Dr. Maria Disselhorst of the Netherlands Cancer Institute in Amsterdam. “The combination of nivolumab plus ipilimumab showed marked efficacy in pa...
Source: Asbestos and Mesothelioma News - February 11, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

State Attorneys General Push for Tougher Asbestos Reporting Rule
A coalition of 15 attorneys general are calling for a tougher asbestos reporting rule as part of the recently-revised Toxic Substances Control Act. Maine’s newly elected Attorney General Aaron Frey said last week the coalition wants to eliminate the exemptions for asbestos within the current Chemical Data Reporting guidelines. The attorneys general have asked U.S. Environmental Protection Agency Acting Administrator Andrew Wheeler to initiate a new rulemaking process, helping it comply with their interpretation of the legislation. “This [new] rule would allow the EPA to comply with the Act by giving it the info...
Source: Asbestos and Mesothelioma News - February 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Senator Probing Johnson & Johnson About Asbestos in Talc
Sen. Patty Murray, D-Wash., has questions, and she wants answers from Johnson & Johnson about its iconic baby powder and the reported link to asbestos-related cancers. Murray recently sent a letter to Johnson & Johnson CEO Alex Gorsky, asking for documentation about past testing for asbestos-tainted talc and communication with the FDA regarding the safety of its product. Murray is a ranking member of the Senate Committee on Health, Education, Labor and Pensions. The letter stemmed from an earlier report by Reuters that Johnson & Johnson hid evidence of asbestos in its product for many years and intentionally mi...
Source: Asbestos and Mesothelioma News - February 4, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news